We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Phathom Pharmaceuticals Inc | NASDAQ:PHAT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.06 | -0.51% | 11.81 | 11.01 | 12.21 | 12.17 | 11.26 | 11.74 | 648,481 | 01:00:00 |
From Jun 2023 to Jun 2024
By Sabela Ojea
Phathom Pharmaceuticals said the U.S. Food and Drug Administration approved Voquezna to treat a type of esophagus inflammation.
The commercial-stage biopharmaceutical company said the FDA approved the novel potassium-competitive acid blocker as a new treatment for adults dealing with erosive esophagitis.
The approval is based on positive results from the phase 3 Phalcon-EE study, which enrolled over 1,000 patients in the U.S. and Europe.
Voqezna is expected to be available in the U.S. in December, the company said.
The FDA approval entitles Phathom Pharmaceuticals to receive a $175 million payment, which will fund the commercial launch.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
November 01, 2023 17:35 ET (21:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Phathom Pharmaceuticals Chart |
1 Month Phathom Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
